Loading...
Market
What will be the outcome of the Phase 2b trial for IMM-1-104 by December 31, 2025?
2
Resolution / Starting Odds
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Immuneering official announcements and clinical trial registries
Story
Immuneering ($IMRX) Announces Positive Phase 2a Data for Pancreatic Cancer Drug
Sep 14, 2024, 07:02 AM
Immuneering has announced positive initial Phase 2a data for its drug IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. The data includes both complete and partial responses, indicating promising efficacy for the treatment. This development is a significant step forward in the fight against pancreatic cancer. The drug is listed under the ticker $IMRX.
View original story
Similar markets
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Yes • 50%
No • 50%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%